The phrase "acting as competitive" is not correct in standard written English.
It may be intended to describe a role or function that involves competition, but the phrasing is awkward and unclear.
Example: "The new marketing strategy is acting as competitive in the current market landscape."
Alternatives: "functioning competitively" or "serving a competitive role".
Despite the large structural and functional diversity of the mammalian antibody repertoire, conventional antibodies (i.e. heterotetramers of two light chains and two heavy chains) acting as competitive enzyme inhibitors are scarcely found in bibliography.
Statin drugs moderate blood cholesterol levels by acting as competitive inhibitors for this enzyme, blocking the biosynthesis of cholesterol early in the synthesis pathway.
Our results showed that most selective compounds against caspsase-3 bind into the substrate binding cleft acting as competitive inhibitors whereas in caspase-7 they bind close to an allosteric site at the dimer interface but since they are weakly bound their presence would not be affecting enzyme dynamics or function.
Since species-specific differences in cofactor preference for in vitro amplification of PrPSc have been reported [30], dextran compounds may interfere with PrPSc formation by acting as competitive inhibitors of the cofactors required for propagation of scrapie PrPSc.
Extensions and elaborations of the indolic side chain have been shown to make effective antiauxins acting as competitive inhibitors.
These receptors bind TRAIL but fail to transmit its apoptosis-inducing signal downstream, thereby acting as competitive inhibitors of TRAIL apoptosis (Ashkenazi and Dixit, 1999).
OPG acts as a decoy receptor for RANKL, thereby acting as a competitive inhibitor.
AIB inhibits ethylene production by acting as a competitive inhibitor of conversion of ACC to ethylene.
As suggested above with regard to chlorophyll synthesis [100], it seems possible that glyphosate and/or AMPA may be acting as a competitive analogue of glycine, potentially outcompeting the amino acid in biological sites and pathways.
TFP was constituted of an elastokine motif (VGVAPG 3, able to increase matrix constituent expression through the stimulation of the elastin-binding protein receptor, a GIL tripeptide occupying matrix metalloproteinase-1 subsites, and a RVRL linker domain acting as a competitive substrate for urokinase.
R103A-EPO is an antagonist capable of inhibiting erythropoietin-dependent proliferation of hematopoietic cells acting as a competitive inhibitor of erythropoietin [32].
